The "MTPAP Gene Spastic Ataxia Type 4 Autosomal Recessive Genetic Test" is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the MTPAP gene. These mutations are responsible for causing Spastic Ataxia Type 4, a rare autosomal recessive neurodegenerative disorder. This condition is characterized by a combination of spasticity and ataxia, affecting an individual's motor skills and coordination. The test is crucial for individuals with a family history of the disorder or presenting symptoms, as it provides definitive genetic evidence of the condition. The cost of the test is 4400 AED, making it a valuable investment for those seeking accurate diagnosis and subsequent management or genetic counseling based on the results.
The AFG3L2 gene plays a critical role in the proper functioning of the human nervous system. Mutations in this gene are associated with Spastic Ataxia Type 5, an autosomal recessive neurological disorder. This condition is characterized by a combination of spasticity and ataxia, which are, respectively, muscle stiffness and a lack of muscle control that leads to speech and movement difficulties. Due to its genetic basis, identifying carriers or affected individuals early can be crucial for management and counseling.
DNA Labs UAE offers a specialized genetic test targeting the AFG3L2 gene to identify mutations that may lead to Spastic Ataxia Type 5. This test is a vital tool for individuals with a family history of the condition or who are experiencing symptoms related to the disorder. The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the lab for specific mutations in the AFG3L2 gene.
The cost of the AFG3L2 gene test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of the information it provides for affected individuals and their families is immeasurable. It not only aids in the diagnosis of Spastic Ataxia Type 5 but also helps in making informed decisions regarding family planning and management of the disorder. With the test available at DNA Labs UAE, individuals have access to critical genetic information that can significantly impact their health management and quality of life.
The "ALS2 Gene Spastic Paralysis Infantile Onset Ascending Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the ALS2 gene. This gene is crucial because its mutations are known to cause a rare neurological disorder characterized by infantile-onset ascending spastic paralysis. This condition typically begins in the lower limbs and progressively affects the upper limbs and other body parts.
The test is crucial for early diagnosis and management of the disorder, helping healthcare professionals devise a suitable treatment and management plan for the affected individuals. The procedure involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for any mutations in the ALS2 gene.
At a cost of 4400 AED, this genetic test is a valuable resource for families seeking answers to unexplained symptoms of progressive muscle stiffness and weakness in their children. Early detection through this test can significantly impact the quality of life of the affected individuals by enabling timely interventions and supportive care. DNA Labs UAE, with its state-of-the-art facilities and expert team, ensures accurate and reliable testing services for this rare genetic disorder.
The IBA57 gene plays a crucial role in the development and functioning of the nervous system. Mutations in this gene are associated with Spastic Paraplegia Type 74, a form of hereditary spastic paraplegia. This condition is characterized by progressive stiffness and contraction (spasticity) in the lower limbs, leading to mobility challenges. As an autosomal recessive disorder, an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
To diagnose this condition, a genetic test targeting the IBA57 gene can be conducted. DNA Labs UAE offers this specialized test, providing a reliable means of confirming the diagnosis for individuals presenting symptoms consistent with Spastic Paraplegia Type 74. The test cost is set at 4400 AED. This genetic analysis not only aids in the diagnosis but also helps in understanding the risk of passing the condition to the next generation, thereby facilitating informed decisions regarding family planning.
The L1CAM gene SPG1 genetic test is a specialized diagnostic procedure designed to identify mutations in the L1 cell adhesion molecule (L1CAM) gene, which are known to cause X-linked hydrocephalus and MASA (mental retardation, aphasia, shuffling gait, and adducted thumbs) syndrome, as well as contribute to the development of spastic paraplegia 1 (SPG1). This test is crucial for individuals showing symptoms of these conditions or for families with a history of related genetic disorders, as early diagnosis can lead to better management and understanding of the condition.
Conducted at DNA Labs UAE, a leading facility in genetic testing and analysis, the L1CAM gene SPG1 genetic test is performed with cutting-edge technology to ensure high accuracy and reliability of results. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific mutations in the L1CAM gene that are indicative of the aforementioned conditions.
The cost of the L1CAM gene SPG1 genetic test at DNA Labs UAE is set at 4400 AED. This cost reflects the comprehensive nature of the test, including the sophisticated analysis and the expertise required to interpret the results accurately. Individuals considering this test are advised to consult with a genetic counselor or healthcare provider to understand the implications of the results and the next steps in the management or treatment of the condition.
The KIF5A Gene SPG10 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the KIF5A gene, which are associated with Spastic Paraplegia 10 (SPG10). SPG10 is a form of hereditary spastic paraplegia, a group of genetic disorders characterized by progressive weakness and spasticity, primarily in the lower limbs. The KIF5A gene plays a critical role in the transport of molecules within neurons, and mutations in this gene can disrupt neuronal function, leading to the symptoms observed in SPG10.
This genetic test involves analyzing the patient's DNA to detect any abnormalities in the KIF5A gene that could lead to SPG10. It is particularly recommended for individuals showing symptoms of hereditary spastic paraplegia or those with a family history of the condition, as it can provide a definitive diagnosis and help guide treatment and management decisions.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the KIF5A Gene SPG10 Genetic Test at DNA Labs UAE is 4400 AED. This price may include the genetic testing procedure, analysis, and a comprehensive report of the findings, although patients are advised to confirm what is included in the cost with the lab directly. The results from this test can be crucial for affected individuals and their families in understanding their condition and planning for the future.
The SPG11 gene is associated with a condition known as spastic paraplegia 11 (SPG11), which is characterized by progressive weakness and stiffness of the legs. This condition is part of a group of genetic disorders known as hereditary spastic paraplegias, which affect the upper motor neurons in the spinal cord, leading to spasticity and paralysis. Mutations in the SPG11 gene disrupt the normal functioning of neurons, particularly in the parts of the brain and spinal cord that control voluntary movements.
To diagnose this condition, a genetic test for the SPG11 gene can be performed. This test involves analyzing the DNA to look for mutations in the SPG11 gene that are known to cause the condition. Genetic testing can help confirm a diagnosis, guide treatment decisions, and inform family planning options for affected individuals and their families.
In the United Arab Emirates, the SPG11 genetic test is available at DNA Labs UAE. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by professionals with expertise in genetic testing, ensuring accurate and reliable results. This test is particularly valuable for individuals with a family history of hereditary spastic paraplegia or related symptoms, as it can provide a definitive diagnosis and help in the management of the condition.
The RTN2 gene SPG12 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the RTN2 gene, which are linked to spastic paraplegia 12 (SPG12), a rare form of hereditary spastic paraplegia. This condition is characterized by progressive weakness and stiffness of the legs, which can lead to severe mobility issues and other neurological complications. The test involves analyzing the patient's DNA to detect any genetic abnormalities that may be responsible for the condition.
Performed at DNA Labs UAE, a leading facility in genetic testing, the RTN2 gene SPG12 genetic test is conducted with high precision and accuracy, utilizing advanced genomic technologies. The cost of the test is 4400 AED, reflecting the comprehensive nature of the analysis and the expertise required to interpret the results. This test is crucial for individuals with a family history of hereditary spastic paraplegia or those exhibiting symptoms, as it can provide a definitive diagnosis, inform treatment strategies, and offer insights into the risk of passing the condition onto future generations.
The SELENON gene rigid spine muscular dystrophy genetic test is a specialized diagnostic tool designed to detect mutations in the SELENON gene, which are associated with rigid spine muscular dystrophy (RSMD). RSMD is a rare genetic disorder characterized by muscle weakness and stiffness, particularly affecting the spine and leading to difficulties in movement and posture. The test is conducted through a sample of the patient's DNA, usually obtained via a blood draw, and it aims to provide crucial information on the genetic underpinning of the condition.
This genetic test is a critical step in the diagnosis and management of RSMD, enabling healthcare providers to tailor treatment plans to the specific needs of the patient, including physical therapy, respiratory support, and other interventions aimed at improving quality of life. It also offers valuable information for family planning and the assessment of risk in family members.
The test is available at DNA Labs UAE, a leading facility in genetic testing and diagnostics. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the comprehensive insights it provides into the patient's genetic profile. DNA Labs UAE employs cutting-edge technology and adheres to stringent quality standards, ensuring accurate and reliable results for patients and their families.
The CAV3 gene rippling muscle disease genetic test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the CAV3 gene, which are associated with the development of rippling muscle disease (RMD). RMD is a rare genetic disorder characterized by muscle stiffness, muscle mounding, and rippling muscle contractions that occur without muscle degeneration. These symptoms are due to mutations in the CAV3 gene, which encodes caveolin-3, a protein crucial for the normal functioning of muscle cells.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the CAV3 gene. The accuracy and specificity of this test make it an invaluable tool for confirming a diagnosis of rippling muscle disease, thereby facilitating appropriate management and treatment strategies for affected individuals.
The cost of the CAV3 gene rippling muscle disease genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the CAV3 gene. By opting for this test, patients and healthcare providers can gain critical insights into the genetic underpinnings of rippling muscle disease, enabling targeted interventions and informed decision-making regarding the patient's health management.
